Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 27Fallopian Tube Neoplasms 9Prostatic Neoplasms 8Breast Neoplasms 8Neoplasms 6Pancreatic Neoplasms 5Endometrial Neoplasms 5Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Mesothelioma 3Lung Neoplasms 3Head and Neck Neoplasms 3Glioblastoma 3Carcinoma, Ovarian Epithelial 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Recurrence 2Mesothelioma, Malignant 2Melanoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urogenital Neoplasms 1Thrombocytopenia 1Stomach Neoplasms 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × niraparib × Clear all
NCT05169437 2025-10-29

PAVO

Tempus AI

Phase 2 Terminated
22 enrolled 17 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT03925350 2021-10-22

Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

California Pacific Medical Center Research Institute

Phase 2 Unknown
41 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡